Visit our Location
11860 Vista Del Sol Dr Suite 105,
El Paso, TX 79936
Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

Tag: vagal tone

ChiroMedBlogvagal tone

GLP-1 Receptor Agonist Insights for Metabolic Health

Understand how GLP-1 receptor agonists for metabolic health can enhance your lifestyle and support metabolic function effectively.

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the evolution, mechanisms, clinical evidence, safety considerations, perioperative care, drug interactions, and practical, long-term use of GLP-1 receptor agonists and the dual GLP-1/GIP agent tirzepatide. Drawing from landmark trials and consensus statements, I explain how these therapies improve weight, glycemia, cardiovascular, and kidney outcomes, why side effects occur, and how to prevent discontinuation. I show how integrative chiropractic care enhances autonomic balance, mitigates pain, preserves lean mass, and supports gastrointestinal tolerance—turning pharmacology into durable, whole-person improvement. You will learn when to choose each agent, how to titrate safely, how to personalize plans for special populations, and how to weave together resistance training, nutrition, breathwork, sleep, and manual therapy for sustained results. I close with clinical observations from my practice to help translate research into patient-centered care.

Why GLP-1 Therapies Matter Now for Obesity and Cardiometabolic Health

Obesity affects over 40% of U.S. adults and drives risk for type 2 diabetes, cardiovascular disease, chronic kidney disease, sleep apnea, osteoarthritis, and several cancers. When lifestyle alone is not enough, modern incretin-based therapies provide high-impact, evidence-backed tools to reduce caloric intake, improve glycemic control, and lower cardiometabolic risk.

  • GLP-1 receptor agonists have become first-line agents in diabetes care and are increasingly central to chronic weight management due to their robust effects on A1C and weight.
  • Dual agonists like tirzepatide amplify effects by engaging GIP alongside GLP-1, often resulting in greater weight loss and improved glycemic control.
  • Integrative practice models—combining chiropractic care, movement, nutrition, and behavioral strategies—help patients maintain function, preserve lean mass, and translate weight loss into daily-life gains.

My goal is simple: equip you to use these therapies confidently and safely, while integrating musculoskeletal and autonomic strategies that make results stick.

Key Terminology and Why These Hormones Matter

  • GLP-1 receptor agonists: Medications that activate the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon, slowing gastric emptying, reducing appetite, and modulating reward circuits. Examples: exenatide, liraglutide, dulaglutide, semaglutide.
  • GIP (glucose-dependent insulinotropic polypeptide): An incretin that enhances insulin secretion; co-agonists that stimulate GIP and GLP-1 receptors (e.g., tirzepatide) can produce synergistic metabolic effects.
  • Glucagon (GCG): Beyond counter-regulating insulin, glucagon influences hepatic glucose output, energy balance, and lipid metabolism. Triple agonists (GLP-1/GIP/glucagon) aim to increase energy expenditure and fat oxidation.
  • Nutrient-stimulated hormone therapies (NUSH): An umbrella for therapies mimicking endogenous gut-hormone responses to food, including GLP-1 and GIP agents.

These terms frame how incretin therapies act across multiple organ systems to deliver outcomes that matter: improved glycemia, reduced appetite, lower weight, and protection for the heart and kidneys.

Mechanisms of Action: The Physiology Behind the Benefits

GLP-1 receptors are widely expressed. Their distribution explains the breadth of clinical benefits and guides how we anticipate and manage effects.

  • Pancreas
    • Beta cells: GLP-1 signaling raises cAMP and activates PKA/Epac, leading to glucose-dependent insulin secretion. Because secretion is tied to ambient glucose levels, these agents have a lower risk of hypoglycemia than non–glucose-dependent secretagogues. Chronic signaling may support beta-cell survival in preclinical models, potentially slowing decline.
    • Alpha cells: GLP-1 suppresses inappropriate glucagon release during hyperglycemia, reducing hepatic gluconeogenesis and glycogenolysis, thereby improving fasting and postprandial glycemia.
  • Gastrointestinal Tract
    • Gastric emptying: GLP-1 slows gastric emptying through vagal and enteric pathways, reducing the rate of glucose appearance and increasing early satiety. Clinically, this lowers postprandial glucose spikes and reduces caloric intake.
    • Satiety signaling: Gut-brain communication via vagal afferents and hindbrain nuclei enhances fullness and reduces meal size.
  • Central Nervous System
    • Hypothalamus: GLP-1 acts on the arcuate and paraventricular nuclei, modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neurons to reduce appetite.
    • Reward circuitry: Activity in the ventral tegmental area and nucleus accumbens is attenuated, blunting the dopamine reward response to hyperpalatable foods. Patients often describe reduced “food noise,” helping sustain dietary changes.
  • Cardiovascular and Renal Systems
    • Endothelium and vasculature: GLP-1 signaling improves endothelial function, reduces inflammation and oxidative stress, and may modulate blood pressure via natriuresis.
    • Kidney: GLP-1 agents reduce albuminuria and slow eGFR decline in at-risk populations via hemodynamic and anti-inflammatory mechanisms.

Why this matters: When we lower A1C without frequent hypoglycemia, patients feel and function better. Appetite suppression paired with slower gastric emptying reduces energy intake. Reward-circuit modulation tackles binge and late-night cravings. Cardio-renal protection delivers benefits beyond weight and glucose.

From Lizard Peptides to Long-Acting Analogs: The Trajectory of Innovation

  • Early discovery: Incretin biology matured in the 1980s, with the identification of GLP-1 and GIP as nutrient-responsive hormones.
  • First-to-market: Exenatide (Byetta), modeled on exendin-4 from Gila monster saliva, launched in 2005—an early example of nature-inspired pharmacology.
  • Human analogs and weekly dosing: Liraglutide (2009) and later extended-release exenatide (2012) improved convenience and adherence.
  • Semaglutide era: Weekly semaglutide (2017; oral formulation in 2019) advanced A1C and weight outcomes and earned chronic weight management approval as Wegovy (2021).
  • Dual agonism: Tirzepatide (2022) combined activation of the GIP and GLP-1 receptors, achieving unprecedented weight and glycemic outcomes.
  • What’s next: Development includes triple agonists, monthly injectables, longer-acting oral agents, and combinations with amylin analogs to optimize tolerability, efficacy, and adherence.

Evidence Highlights: What the Strongest Trials Show

  • Weight and Glycemic Control
    • Liraglutide SCALE: ~8% mean weight loss at 56 weeks with improved cardiometabolic markers (Pi-Sunyer et al., 2015).
    • Semaglutide STEP:
      • STEP 1: ~15% mean weight loss at 68 weeks in adults with overweight/obesity (Wilding et al., 2021).
      • STEP 2: ~9.6% mean weight loss with A1C reductions of ~1.6–2.0% in type 2 diabetes (Davies et al., 2021).
      • STEP 5: >13% mean weight loss beyond one year, supporting durability (Rubino et al., 2022).
    • Tirzepatide SURMOUNT: 15–20% mean weight loss at 72 weeks; some cohorts approach ~25% (Jastreboff et al., 2022; Frias et al., 2023).
  • Cardiovascular and Renal Outcomes
    • Semaglutide SELECT: ~20% reduction in 3-point MACE in adults with obesity and established cardiovascular disease but without diabetes—hard cardiovascular benefits in a non-diabetic population (Nissen et al., 2023).
    • HFpEF with obesity: Semaglutide improved heart failure symptoms, physical limitations, and exercise capacity (Kitzman et al., 2023).
    • Kidney outcomes: Semaglutide reduced a composite kidney outcome by ~22% among patients with obesity and cardiovascular disease (Mann et al., 2021).

In practice, I align therapy with top patient goals—glycemia, weight, heart/kidney protection—and pair medication with structured nutrition and resistance training to preserve lean mass and function.

Safety Profile: Adverse Effects and How to Mitigate Them

Early gastrointestinal effects reflect pharmacodynamic changes (delayed gastric emptying, central satiety) and typically improve with slow titration.

  • Common effects
    • Nausea, vomiting, diarrhea, abdominal discomfort, dyspepsia, decreased appetite.
    • Taste changes or aversion to fried/greasy foods
  • Less common but important
    • Gastroparesis or bowel obstruction risk in those with severe baseline dysmotility
    • Pancreatitis: monitor for persistent severe upper abdominal pain radiating to the back
    • Gallbladder disease: cholelithiasis/cholecystitis risk during rapid weight loss
    • Acute kidney injury: dehydration from vomiting; protect hydration and monitor renal function
    • Hypoglycemia: mainly with concurrent insulin or sulfonylureas; proactively reduce doses
    • Diabetic retinopathy: rapid A1C drops can transiently worsen retinopathy; coordinate care
    • Body composition: risk of lean mass loss; prioritize protein and resistance training
  • Contraindications and boxed warning
    • Thyroid C-cell tumors: contraindicated with personal/family history of MTC or MEN2
    • Avoid in severe GI disease, history of pancreatitis, pregnancy, or breastfeeding.
  • Patient counseling essentials
    • Explain theoretical thyroid risk and symptoms (neck mass, dysphagia, hoarseness, dyspnea)
    • Routine calcitonin or thyroid ultrasound screening is not recommended in asymptomatic users.
    • Avoid compounded products; stick to FDA-approved medications dispensed by licensed pharmacies.

Dosing Strategies: Why “Start Low, Go Slow” Works

The biology is clear: early GI symptoms represent intended effects on gastric emptying and satiety. The nervous system adapts over weeks. We protect adherence by moving at the body’s pace.

  • Begin at the lowest dose and extend titration steps if moderate nausea or early satiety interferes with intake.
  • Encourage small, protein-forward meals; limit high-fat, fried, and very sweet foods, which can exacerbate nausea.
  • Promote hydration and electrolytes, especially during the first 8–12 weeks.
  • Pair with resistance training immediately to signal lean mass retention.
  • If adding to insulin or sulfonylureas, proactively reduce those agents and monitor with CGM when available.

Perioperative Care: GLP-1 Use and Aspiration Risk

Consensus statements from anesthesiology and gastroenterology groups (2024) indicate that most patients can continue GLP-1 therapy before procedures. For high GI risk (marked nausea, vomiting, gastroparesis), a pre-procedural liquid diet mitigates aspiration risk.

  • Ask specifically about GLP-1 use during pre-op assessments.
  • Screen for GI symptoms and gastroparesis.
  • Coordinate with anesthesia on individualized liquid diet plans and NPO timing.
  • Resume standard dosing post-operatively once oral intake and hydration normalize.

Delaying gastric emptying is part of how these drugs work; perioperative plans must respect this physiology while balancing airway safety.

Major Drug Interactions Clinicians Must Check

  • Insulin and Sulfonylureas
    • Risk: additive hypoglycemia
    • Strategy: proactively reduce doses, monitor SMBG/CGM
  • Narrow Therapeutic Index Drugs
    • Mechanism: delayed gastric emptying can alter absorption
    • Examples: certain antiepileptics, warfarin (monitor INR), select immunosuppressants
    • Strategy: intensified monitoring during initiation/up-titration; adjust timing or formulation
  • Tirzepatide and Oral Contraceptives
    • Guidance: Use non-oral contraception for 4 weeks after initiation and each dose escalation
  • DPP-4 inhibitors
    • Evidence: combining DPP-4 inhibitors with GLP-1 agonists adds side effects without benefit; avoid combination per ADA guidance

Public Health Safety: Counterfeit and Unregulated Online Sales

Counterfeit or “research use only” GLP-1 products marketed online pose serious risks: contamination, mislabeled doses, or entirely different compounds. Dosing errors can trigger severe GI events, dehydration, or destabilize glycemia.

  • Educate patients to use only FDA-approved medications via licensed pharmacies.
  • Verify NDC codes, lot numbers, and pharmacy licensure.
  • Document counseling and sourcing verification.

In my clinics, atypical adverse reactions have resolved once verified formulations were used.

FDA Safety Monitoring: Suicidal Ideation Reports Under Evaluation

In 2024, the FDA began evaluating reports of suicidal ideation among users of GLP-1 agents and tirzepatide. No causal link has been established, but vigilance is appropriate.

  • Baseline screening for mood, suicidality, and eating disorders
  • Repeat checks after each dose escalation and at quarterly maintenance visits
  • Collaborate with behavioral health; protect sleep and circadian regularity

Appetite suppression and rapid weight change intersect with mood pathways; proactive monitoring supports safety and adherence.

Long-Term Use: Why Continuing Therapy Matters

Obesity is a chronic, relapsing disease with hypothalamic set points, adipocyte signaling, and metabolic adaptation. Discontinuation often leads to a regain.

  • STEP 1 extension: After discontinuing semaglutide, participants regained roughly two-thirds of the weight lost at one year (Rubino et al., 2022).
  • SURMOUNT-4: Continuing tirzepatide maintained losses; switching to placebo led to ~14% weight regain by week 52 (Jastreboff et al., 2023).

Interpretation: Long-term pharmacotherapy—such as antihypertensives—helps maintain gains in weight, glycemia, and risk reduction. Maintenance plan.

Discontinuation: Why Patients Stop and How to Prevent It

Real-world discontinuation can be high in the first year. Top drivers include adverse effects, cost, access gaps, and unmet expectations.

  • Start low, go slow; hold dose increases when symptoms arise.
  • Front-load education on expected GI effects and management strategies.
  • Build multidisciplinary support: dietitians, pharmacists, behavioral health, and integrative clinicians.
  • Offer coverage, navigation, and consider manufacturer assistance.

Adherence is a physiologic outcome—patients stay the course when symptoms are managed, costs are addressed, and goals feel meaningful.

Guideline Alignment: Where GLP-1 Therapies Fit

  • Diabetes (ADA, AACE): Recommend GLP-1 receptor agonists for patients with type 2 diabetes who have or are at high risk for ASCVD, CKD, HF, obesity, or MASLD. Focus on cardiometabolic risk beyond A1C (American Diabetes Association, 2024; American Association of Clinical Endocrinology, 2023).
  • Obesity (ACC): GLP-1 agents are first-line pharmacotherapy for weight management without requiring lifestyle “failure,” given their superior efficacy compared with lifestyle alone and a lower risk than bariatric surgery for many patients (American College of Cardiology, 2024).

Personalizing Therapy: Matching the Agent to the Patient

  • Type 2 diabetes with ASCVD: Favor agents with proven MACE reduction (e.g., semaglutide); coordinate with cardiology.
  • CKD or albuminuria: GLP-1 RAs offer renal benefits; monitor eGFR; consider SGLT2 inhibitors for additive renal/HF protection.
  • History of gallbladder disease: Titrate slowly, promote steady calorie deficits, and monitor biliary symptoms.
  • GI motility concerns: Avoid or use extreme caution with baseline gastroparesis.
  • Reproductive planning: Avoid during pregnancy and breastfeeding; counsel on contraception; with tirzepatide, avoid oral contraceptives during initiation and dose escalations.
  • Co-therapy with insulin/sulfonylureas: Reduce doses and use CGM to minimize hypoglycemia.

Integrative Chiropractic Care: Amplifying Outcomes and Preserving Function

As a clinician working at the intersection of neuromusculoskeletal medicine and metabolic health, I integrate chiropractic modalities alongside GLP-1 therapy to improve adherence, comfort, and functional capacity.

  • Chiropractic and neuromusculoskeletal support
    • Spinal and extremity adjustments optimize joint mechanics and reduce nociceptive drive, making early exercise more comfortable. Less pain improves sleep and autonomic balance, which supports glycemic control and fat loss.
    • Soft-tissue therapies and myofascial release address compensations and movement restrictions that can worsen with rapid weight change, improving range of motion and exercise tolerance.
    • Neurodynamic and proprioceptive training enhance motor control and balance, enabling safe progression to resistance training, which is essential for preserving lean mass.
  • Exercise and body composition
    • Focus on progressive resistance training (2–4 sessions/week) with compound movements; phase in isometrics and closed-chain exercises when pain or mobility limits exist.
    • Build Zone 2 aerobic base to support mitochondrial health, insulin sensitivity, and recovery without driving excessive hunger.
    • Track functional benchmarks (sit-to-stand reps, loaded carries, gait speed) to reinforce adherence.
  • Nutrition and recovery
    • Protein-first meals: Target 1.2–1.6 g/kg/day to preserve lean mass and mitigate hunger variability; use protein shakes or Greek yogurt plus electrolytes when appetite is low.
    • Emphasize micronutrient density: potassium, magnesium, and omega-3s to support cardiometabolic health and reduce cramping.
    • Meal pacing aligns with delayed gastric emptying and reduces the risk of nausea.
  • Autonomic regulation and behavior
    • Diaphragmatic breathing and brief HRV-guided practices before meals improve GI comfort and reduce stress-eating triggers.
    • Sleep optimization helps stabilize hunger hormones (ghrelin and leptin) and improves glucose control.
    • Cognitive-behavioral frameworks help patients leverage reduced food noise and build new routines.

Physiologic coherence: Pain reduction lowers sympathetic drive; movement sends mechanotransduction signals to muscle and bone; autonomic balance enhances vagal inputs that support gastric motility and satiety. Integrative care makes GLP-1 therapy more tolerable and more effective.

Clinical Observations from My Practice

From my work shared at Chiromed.com and my professional collaborations:

  • Initiating GLP-1 therapy alongside structured resistance training and pain-modulating manual care reduces fatigue and improves willingness to train, protecting lean mass and posture during weight loss.
  • Neck and low-back discomfort may transiently flare as body mass redistributes; timely adjustments and soft-tissue work smooth transitions and prevent activity drop-off.
  • Simple breathwork before meals reduces GI complaints and improves pacing, suggesting autonomic co-regulation complements delayed gastric emptying.
  • The most durable changes occur when we measure function—gait speed, grip strength, sit-to-stand improvements—rather than focusing only on the scale.

For more of my clinical insights and interprofessional collaborations, visit:

Case Study: Re-Initiating Semaglutide Safely After an Interruption

Patient: Amanda Chen, 58, T2D, BMI 36, osteoarthritis. Previously tolerated semaglutide at 1.7 mg weekly, lost 12 lbs, then paused therapy for six weeks due to GI illness. She wants to restart at 1.7 mg.
Clinical reasoning: Even after prior tolerance, restarting at a high dose post-gap increases the risk of GI side effects due to resetting of gastric emptying and gut–brain signaling.
Best practice:

  • Restart at 0.25 mg weekly for 4 weeks, then re-titrate per standard protocol:
    • 0.25 mg weekly × 4 weeks
    • 0.5 mg weekly × 4 weeks
    • 1.0 mg weekly × 4 weeks
    • 1.7 mg weekly × 4 weeks (if indicated for weight)
    • 2.4 mg weekly (target for obesity indications), pacing individualized
  • If adverse effects occur: pause escalation; maintain dose longer until tolerance improves.

Monitoring:

  • During titration: monthly visits to assess GI effects, hydration, weight change, glycemia, blood pressure, and adherence.
  • Maintenance: quarterly follow-up; more frequent if combining with insulin or in older adults with CKD risk.

Safety parameters:

  • Glycemia: SMBG/CGM; reduce insulin/sulfonylurea doses to prevent hypoglycemia.
  • Renal: serum creatinine/eGFR; ensure hydration, especially if vomiting/diarrhea or diuretic use.
  • Pancreatitis: persistent upper abdominal pain and vomiting; check lipase promptly.
  • Gallbladder: RUQ pain; consider ultrasound if symptomatic.
  • Thyroid/MTC risk: screen personal/family history for MEN2/MTC.
  • Mental health: mood checks and suicidality screening during escalations and milestones.

Counseling for GI tolerance:

  • Hydration: 2–3 liters/day unless contraindicated; separate fluids from meals if reflux is prominent.
  • Meal structure: smaller, protein-forward, nutrient-dense meals; avoid large, high-fat/fried meals early.
  • Triggers: limit carbonation and alcohol; avoid lying down after meals.
  • Constipation plan: fiber, magnesium citrate or osmotic laxatives as needed, daily walking.
  • Nausea strategies: ginger tea, cooled foods, bland starters; consider dose holds rather than reductions when symptoms are transient.
  • Expectations: normalize mild GI effects; reinforce adherence.

Adaptations:

  • Low responders (<5% weight loss at 12–16 weeks): verify adherence, timing, nutrition, sleep; consider longer holds at intermediate doses or switching agents if the maximally tolerated dose yields inadequate response.
  • Excessive responders (frailty, BMI <18.5, low protein intake): evaluate for endocrinopathies, malabsorption, or disordered eating; reduce dose or pause; engage dietitian and behavioral health.

Eating Right to Feel Better- Video

Integrative Nutrition: The MEAL Framework

Nutrition is integral to efficacy and safety; I use the MEAL framework:

  • M: Muscle maintenance
    • Set protein targets at 1.2–1.6 g/kg/day to preserve lean mass.
    • Pair with resistance training to counter sarcopenia and sustain resting metabolic rate.
  • E: Energy balance
    • Align caloric intake with satiety cues; maintain micronutrient sufficiency.
    • Spread intake throughout the day to stabilize energy and blood glucose levels.
  • A: Avoid side effects
    • Constipation: fiber, fluids, magnesium, or PEG as needed, daily movement.
    • Nausea/GERD: small portions, low-fat cooking, avoid carbonation and late meals; consider short-term H2 blockers or PPIs when necessary.
  • L: Liquid intake
    • 2–3 liters/day supports motility and reduces dizziness/fatigue from reduced intake; add electrolytes with physical activity or heat exposure.

Movement and Resistance Training: Protecting Lean Mass and Metabolic Rate

Exercise prescriptions should be specific and progressive:

  • Aerobic baseline: build toward 150 minutes/week moderate intensity or 75 minutes/week vigorous.
  • Resistance training: 60–90 minutes/week over 2–3 sessions to stimulate muscle protein synthesis.
  • Daily movement: 30–60 minutes of light-to-moderate activity supports glycemic control and GI motility.
  • Balance and mobility are essential in older adults; they reduce fall risk and support independence.
  • Functional measures: grip strength and 6-minute walk tests track resilience and guide load.

This protects lean mass, stabilizes metabolism, and makes pharmacologic weight loss translate into better function.

Practical Clinical Pearls: What Works Best

  • Start with the why: match therapy choice to indications—T2D, obesity, ASCVD risk, CKD, MASLD—and articulate goals beyond A1C.
  • Dosing discipline: start low, go slow; hold at a dose rather than escalate into intolerance.
  • Education first: teach injection technique, site rotation, and what to expect in the first 4–8 weeks.
  • Prevent hypoglycemia: down-titrate insulin or sulfonylureas; use CGM when available.
  • Watch gallbladder and pancreas: RUQ pain or persistent nausea warrants evaluation; check lipase and consider ultrasound.
  • Renal protection: monitor eGFR, especially if vomiting or diuretic use is present; emphasize hydration.
  • Reproductive safety: avoid in pregnancy and lactation; counsel on contraception. With tirzepatide, avoid oral contraceptives for 4 weeks after start/escalation.
  • Thyroid precautions: screen for MTC/MEN2 history; discuss boxed warning implications.
  • Expectation management: set a realistic pace for weight loss; focus outcomes on function, labs, and cardiometabolic risk.
  • Team-based care: dietitians, diabetes educators, pharmacists, behavioral health, and integrative clinicians raise success and reduce discontinuation.

Common Pitfalls to Avoid

  • Rapid escalation: rushing doses leads to dropout; titration patience preserves adherence.
  • Insufficient counseling: early discontinuation is preventable with anticipatory guidance.
  • Overlooking interactions: reassess narrow-therapeutic-index drugs, insulin/sulfonylurea dosing, and contraception with tirzepatide.
  • Hydration gaps: many symptoms improve with fluids and electrolytes; formalize targets.
  • Missing pancreatitis signals: persistent or escalating abdominal pain deserves prompt workup.
  • Skipping thyroid/MEN2 screening: maintain vigilance given labeled risks.
  • Scale-only thinking: anchor goals in function, labs, and risk, not just pounds.
  • Cost surprises: verify coverage, explore assistance, plan contingencies.
  • Social determinants: address food access, transportation, and home stability.
  • Set-and-forget: active monitoring is essential during the first 3–6 months and after dose changes.

Putting It All Together: A Patient-Centered, Integrative Roadmap

  • Verify medication source; prescribe only FDA-approved products via licensed pharmacies.
  • Screen for mood/eating disorders, pancreatitis/gallbladder risks, MEN2/MTC history.
  • Plan insulin/sulfonylurea reductions, CGM/SMBG, hydration, and nutrition strategies.
  • Initiate semaglutide at 0.25 mg weekly for 4 weeks; escalate only when tolerated.
  • Build a nutrition plan using the MEAL framework with protein targets and micronutrient sufficiency.
  • Prescribe movement: progressive aerobic minutes, resistance training 2–3 days/week, plus balance and mobility.
  • Integrate chiropractic care for autonomic regulation, pain control, and kinetic chain optimization.
  • Schedule monthly check-ins during titration; quarterly thereafter; more frequent if medically complex.
  • Prepare for surgery by collaborating with anesthesia; use liquid diet protocols for high-risk cases.
  • Reassess response at 12–16 weeks; adapt the dose or switch agents as needed; always align with patient goals and values.

By weaving together pharmacology, lifestyle medicine, and integrative chiropractic strategies, we make GLP-1 therapies safer, more tolerable, and longer-lasting—delivering the cardiometabolic benefits patients deserve while preserving function and quality of life.

References

SEO tags: GLP-1 receptor agonists, semaglutide, tirzepatide, incretin therapy, obesity treatment, weight loss medication, type 2 diabetes, cardiovascular outcomes, kidney protection, SURMOUNT trials, STEP trials, SELECT trial, integrative chiropractic care, manual therapy, resistance training, satiety hormones, gastric emptying, reward circuitry, pancreatitis risk, gallbladder disease, boxed warning, MTC, MEN2, gastroparesis, A1C reduction, evidence-based medicine, functional medicine, body composition, lean mass preservation, chronic pain and obesity, HFpEF and obesity, perioperative GLP-1 management, drug interactions GLP-1, oral contraceptives tirzepatide, DPP-4 inhibitors, hydration, MEAL framework nutrition, autonomic balance, vagal tone, case study semaglutide restart, dose titration, ADA guidelines, AACE guidelines, ACC consensus, counterfeit Ozempic, FDA safety communication

The Gut-Immune System and Hormones Role in Overall Wellness

Dive into the world of the gut-immune system and hormones and their crucial role in supporting immune health and overall wellness.

Abstract

I wrote this educational post to share how I moved from medication stacks to a systems-biology model that begins in the gut and extends through the immune, endocrine, and nervous systems. Drawing on modern methods such as metagenomic sequencing, metabolomics, intestinal permeability assays, and autonomic measures (e.g., HRV), I explain how dysbiosis, leaky gut, and LPS-driven inflammation disrupt estrogen metabolism, thyroid hormone conversion, insulin sensitivity, and mood. You will learn why supporting the estrobolome, optimizing vitamin D3–K2–A cofactors, and balancing iodine–selenium for thyroid are pivotal. I discuss practical protocols using diet, prebiotics, probiotics, butyrate support, DIM/I3C, calcium D-glucarate, glutamine, methylation cofactors, and, when appropriate, shilajit to sustain free testosterone. I also show where integrative chiropractic care fits: improving vagal tone, diaphragmatic mechanics, and autonomic balance to normalize motility, lower inflammation, and help good plans work. Throughout, I reference my clinical observations from ChiroMed and the latest findings from leading researchers, so you can see the rationale behind each step and apply this roadmap safely and effectively.

Why I Now Start With The Gut, Then Layer Hormones, Thyroid, And Structure

I trained in conventional models and spent years optimizing hormones and metabolism. I prescribed intensively, studied incretins and GLP-1, and did everything I could to improve diabetes and endocrine care. Many patients improved—but too many plateaued. The turning point came when I consistently addressed gut integrity and the neuroimmune axis first: patients’ medication burdens decreased, weight and energy normalized, and mood and cycles stabilized. When I dug deeper into the 25–30% who still struggled, I found a common thread: dysbiosis, intestinal permeability, and autonomic dysregulation blocked progress.
My clinical lesson: persistent symptoms usually reflect a convergence of microbiome imbalance, barrier dysfunction, immune activation, autonomic imbalance, and environmental mismatch. These systems converge in the gut. That’s why my care integrates functional nutrition, targeted supplementation, hormone and thyroid optimization, and integrative chiropractic to restore nervous system balance and biomechanics. Across my clinical work at ChiroMed and case reflections I share on LinkedIn, a gut-first framework reliably transforms outcomes (Jimenez, n.d.-a; Jimenez, n.d.-b).

The Gut Microbiome As A Neuroendocrine And Immune Control Center

The microbiome is a living organ system. In a healthy state, it:

  • Produces short-chain fatty acids (SCFAs)—especially butyrate, propionate, and acetate—that fuel colonocytes, tighten epithelial tight junctions, and tame inflammation (Canfora et al., 2019).
  • Trains GALT and regulatory T cells (Tregs), fostering immune tolerance (Turnbaugh & Gordon, 2019).
  • Maintains barrier integrity, preventing lipopolysaccharide (LPS) translocation and downstream TLR4–NF-κB signaling (Camilleri, 2019).
  • Modulates neurotransmitters and the HPA axis, influencing serotonin via enterochromaffin cells and stress resilience (Cryan & Dinan, 2015).
  • Shapes hormone metabolism, including the estrobolome, insulin sensitivity, and thyroid conversion.

When dysbiosis develops, we see reduced butyrate-producing bacteria, an excess of pathobionts, and elevated beta-glucuronidase—an enzyme that can deconjugate estrogens and promote estrogen recirculation. Clinically, this presents as bloating, irregular stools, acne, brain fog, fatigue, weight plateaus, and hormone therapy that “doesn’t stick.” Mechanistically, increased LPS fuels systemic inflammation and insulin resistance; reduced SCFAs loosen junctions and weaken mucosal defense; and neuroendocrine signaling drifts toward anxiety, low mood, and poor sleep.

Intestinal Permeability, Zonulin, and the Inflammation–Endocrine Loop

“Leaky gut” is a measurable phenomenon. Tight junctions—regulated by proteins like claudin, occludin, and zonulin—hold epithelial cells together. When zonulin rises in response to gluten, infections, dysbiosis, or stress, the junctions loosen, allowing dietary antigens and microbial fragments to enter the circulation (Fasano, 2012). The consequences:

  • Immune activation: Elevated TNF-α and IL-6 amplify systemic inflammation.
  • Endocrine disruption: Cytokines increase cortisol and insulin, blunt T4→T3 conversion, and alter sex hormone balance.
  • Metabolic effects: Raised insulin and cortisol promote fat storage and alter appetite circuits.

Repeated postprandial endotoxemia (LPS spikes after meals) is well documented with high-fat, ultra-processed diets, fueling insulin resistance and barrier erosion (Cani et al., 2007). In my practice, I routinely see elevated zonulin, LPS-binding protein, low SCFAs, and high beta-glucuronidase in stressed, symptomatic patients. When we seal the barrier and calm LPS, endocrine therapies begin to work the way we expect.

The Estrobolome, Beta-Glucuronidase, And Estrogen Recirculation

The estrobolome—the gut microbial genes that metabolize estrogens—determines whether estrogens are excreted or recirculated. In the liver, estrogens are conjugated (often glucuronidated) and excreted via bile. If the microbiome produces excess beta-glucuronidase, it deconjugates estrogens in the intestine, thereby enabling reabsorption through the intestinal wall (Plottel & Blaser, 2011; Flores et al., 2012). Add constipation, and you compound recirculation. Clinically, I see:

  • Worsened PMS, mastalgia, fibrocystic changes, and heavier cycles.
  • Frustration with hormone therapy due to increased metabolites returning to circulation.
  • Mood variability and breast density changes when the 2-OH:16-OH balance is unfavorable.

Supporting fiber, calcium D-glucarate, DIM/I3C, methylation cofactors, bile flow, and daily bowel movements can reverse this loop.

PCOS, Endometriosis, And The Gut–Hormone Axis

  • PCOS: Dysbiosis raises LPS and zonulin, driving inflammation and insulin resistance, which increases ovarian theca cell androgen production. Result: hyperandrogenism, anovulation, acne, and metabolic risk (Qi et al., 2022). When I rebuild the barrier, raise SCFAs, and add resistance training with targeted nutrition, fasting insulin drops, cycles stabilize, and skin clears.
  • Endometriosis: Elevated beta-glucuronidase and permeability raise circulating estrogen and pelvic inflammation. Estrogen metabolism favors 2-hydroxylation over proliferative or genotoxic pathways when supported with DIM, I3C, methylation, and glucuronidation aids (Yager & Davidson, 2006; Taylor et al., 2020). My patients often report lighter cycles and reduced pain when transit improves, and recirculation decreases.

Thyroid Conversion, Iodine–Selenium Synergy, and Hashimoto’s

Thyroid function hinges on substrate availability and redox safety:

  • Iodine is essential for T4/T3 synthesis, but it must be managed carefully—especially in autoimmune thyroiditis.
  • Selenium-dependent enzymes (glutathione peroxidases, deiodinases) detoxify H2O2 used by TPO and convert T4 to T3. Low selenium levels increase oxidative stress and can heighten antibody activity; supplementation can lower TPO antibody levels in some patients (Gärtner et al., 2002).

In Hashimoto’s, dysbiosis and intestinal permeability elevate cytokine levels, impairing T4→T3 conversion and nutrient absorption (Caturegli et al., 2014). Correcting the microbiome, supporting the barrier, and using vitamin D3–K2–A with magnesium (for vitamin D metabolism) improves immune tolerance and thyroid status. In my clinic, combining selenium (100–200 mcg/day) with gut repair and stress modulation often stabilizes symptoms and antibody trends.

Vitamin D3, K2, Magnesium, And Vitamin A: Directing Calcium And Calming Immunity

Many patients take vitamin D3 without cofactors. For safety and efficacy:

  • Magnesium supports the enzymes that convert D into its active forms.
  • Vitamin K2 (MK-7) activates osteocalcin and matrix Gla protein (MGP), directing calcium to bones and away from arteries (Beulens et al., 2013).
  • Vitamin A (retinol) works synergistically with D and K to balance bone remodeling and epithelial integrity.

I generally target 25(OH)D at 50–70 ng/mL, titrating based on labs, with D3 taken with fat and magnesium, plus K2 (and judicious vitamin A when indicated) (Pilz et al., 2019; Mitchell et al., 2022). Clinically, this reduces musculoskeletal aches, improves mood and immune balance, and safeguards vascular health during endocrine optimization.

Akkermansia, SCFAs, And Metabolic Flexibility

I pay close attention to Akkermansia muciniphila, a mucin-degrading bacterium associated with stronger mucus layers and better metabolic profiles. Low levels of Akkermansia correlate with barrier fragility and weight-loss resistance (Everard & Cani, 2013). When I support mucosal nutrition (polyphenols from berries and pomegranates; prebiotic fibers; omega-3s), Akkermansia often rebounds. When combined with fiber-induced SCFAs, patients regain insulin sensitivity, see improved fasting glucose, and break stubborn weight plateaus.

Evidence-Based Tools That Inform Personalization

Modern research methods help move from guesswork to precision:

  • Metagenomics identifies microbial composition and functional genes (e.g., SCFA producers, Enterobacteriaceae) to target interventions (Turnbaugh & Gordon, 2019).
  • Metabolomics measures functional outputs—such as SCFAs, bile acids, and indoles—to gauge progress.
  • Permeability assays (e.g., serum zonulin, lactulose/mannitol) and markers like LPS-binding protein quantify barrier function (Camilleri, 2019).
  • Neurogastroenterology and HRV assessments tailor autonomic and motility interventions (Tracey, 2002).

This data-driven approach, combined with clinical observation, improves accuracy, safety, and recovery speed.

Integrative Chiropractic Care: Why Structure And Autonomics Matter

As a chiropractor and nurse practitioner, I witness how biomechanics and the autonomic nervous system shape gut and endocrine function:

  • Vagal tone: Gentle cervical work, rib mechanics, diaphragmatic release, and paced breathing increase parasympathetic output, improving gastric accommodation and GI motility, while reducing visceral hypersensitivity.
  • Spinal and pelvic mechanics: Thoracolumbar and sacral segments modulate sympathetic and parasympathetic outflow to the GI tract; restoring mobility reduces nociceptive drive and systemic cytokine levels.
  • Movement prescriptions: Rhythmic aerobic work and resistance training improve insulin sensitivity and myokine profiles, enhancing metabolic resilience.

In my practice, adding HRV-guided breathing, diaphragmatic training, and targeted adjustments accelerates gut recovery and stabilizes mood and sleep. Structural integration is not optional; it is central to steady autonomic balance and endocrine stability (Tracey, 2002; Cryan & Dinan, 2015; Jimenez, n.d.-a; Jimenez, n.d.-b).

DIM, I3C, And Safer Estrogen Metabolism

Diindolylmethane (DIM) and indole-3-carbinol (I3C) help steer estrogen toward the 2-hydroxy (2-OH) pathway, away from 4-OH quinone-prone and 16-OH proliferative metabolites. Mechanisms include modulation of CYP enzymes and support of COMT-mediated methylation (Bradlow, 2019; Kabat et al., 2006). In practice:

  • Women: DIM 100–150 mg/day, titrating up to 300 mg/day when PMS, mastalgia, or estrogen dominance persists.
  • Men: DIM 300 mg/day, up to 600 mg/day in select prostate risk scenarios while monitoring.

I pair DIM with methylated B vitamins and sulforaphane (Nrf2 activation) to ensure conjugation and detox pathways keep pace (Singh et al., 2011). Clinically, patients report improved breast density profiles and better tolerance to HRT when DIM is maintained.

Calcium D-Glucarate, Methylation, Bile Flow, And Daily Excretion

To reduce beta-glucuronidase reactivation and enterohepatic recirculation, I use:

  • Calcium D-glucarate to support glucuronidation.
  • Methylation support (methylfolate, methylcobalamin, B6/P5P, TMG) to detoxify catechol estrogens and maintain COMT function—especially when 4-OH is elevated.
  • Bile flow support with bitters (e.g., gentian, dandelion) and hydration to carry conjugated estrogens into the intestine.
  • Transit optimization with fiber and gentle movement. Constipation is a nonstarter—daily bowel movements are mandatory for estrogen safety.

This Phase I–II–III strategy ensures metabolites are formed safely (Phase I), conjugated (Phase II), and eliminated (Phase III).

Glutamine, Zinc Carnosine, And Mucosal Repair

When permeability is high or mucosal stress is severe, I deploy:

  • L-glutamine to fuel enterocytes and bolster tight junction protein expression.
  • Zinc carnosine to stabilize mucosal surfaces and reduce oxidative stress (Ueda et al., 2007).
  • Omega-3s and demulcents as needed.

Patients often experience reduced bloating, better stool quality, and calmer skin when mucosal repair is prioritized.

Shilajit And Free Testosterone: Sustaining Benefits Across Pellet Cycles

Late in testosterone pellet cycles, many patients report symptom drift despite acceptable total testosterone. The culprit is often a decline in free testosterone, the bioavailable fraction that drives receptor signaling. Purified shilajit has shown significant increases in both total and free testosterone (e.g., ~31% and ~51% respectively at 250 mg twice daily in a randomized, placebo-controlled trial), likely via fulvic acid–mediated mitochondrial and transport effects (Pandit et al., 2016). In my clinic:
Adding purified shilajit during the latter half of a pellet cycle stabilizes free testosterone without pushing total levels into side-effect territory.
Patients report steadier energy, drive, and recovery.
I integrate shilajit into a comprehensive HRT support stack (DIM, methylated B’s, sulforaphane, CoQ10) to support balanced metabolism and oxidative protection.
For women with PCOS or androgen sensitivity, I avoid raising androgens and instead emphasize estrogen detoxification and an insulin-sensitizing lifestyle.

Practical, Stepwise Clinical Plan

Here is how I typically structure care:

  • Phase 1: Calm the fire
    • Remove ultra-processed foods, dyes, and excess alcohol.
    • Establish hydration, protein adequacy, and high-fiber, polyphenol-rich meals.
    • Start multi-strain probiotics, prebiotics (inulin, FOS, GOS, resistant starch), and L-glutamine; add zinc carnosine if mucosal stress is evident.
    • Begin paced breathing (≈6 breaths/min), humming or gargling, and chiropractic sessions to downshift sympathetic tone.
    • Target sleep: a consistent schedule, a cool, dark room, and morning light.
  • Phase 2: Restore and rebalance
    • Add DIM/I3C based on symptoms or metabolite data; support methylation (methylfolate, B12, B6, TMG).
    • Introduce calcium D-glucarate for glucuronidation; enhance transit with diverse fibers.
    • Train with progressive resistance (3x/week) and zone 2 cardio (2x/week).
    • Ensure daily bowel movements and support bile flow with bitters.
  • Phase 3: Optimize and personalize
    • Reassess stool metrics (zonulin, SCFAs, beta-glucuronidase, Akkermansia) and hormone metabolites.
    • Correct nutrient deficits (vitamin D, magnesium, omega-3s, iron, zinc).
    • Support Akkermansia with polyphenols and mucin-feeding fibers; maintain D3–K2–A for calcium handling and immune balance.
    • For pellet-based HRT, consider shilajit to sustain free testosterone; for PCOS or estrogen dominance, lean on detox supports without increasing androgens.
    • Maintain integrative chiropractic care to reinforce autonomic balance and movement quality.

Modulating Women’s Hormones- Video

Clinical Observations From My Practice

From my work at ChiroMed and professional updates I share on LinkedIn:

  • Patients with “great labs” but persistent symptoms often harbor dysbiosis, increased permeability, or elevated beta-glucuronidase—addressing these unlocks progress (Jimenez, n.d.-a; Jimenez, n.d.-b).
  • Pairing resistance training with gut repair stabilizes cycles and insulin in PCOS; skin and mood follow.
  • Akkermansia repletion tracks with breaking weight-loss plateaus, even after GLP-1 use.
  • Integrative chiropractic care improves adherence and resilience—when pain and sleep improve, nutrition and movement protocols stick, accelerating gut and hormone balance.

Why These Techniques Work: Physiology-First Reasoning

  • Prebiotics and fiber → raise SCFAs, especially butyrate, tightening junctions and lowering inflammatory signaling (Canfora et al., 2019). This reduces LPS leakage and stabilizes endocrine pathways.
  • Synbiotics (probiotics + prebiotics) → re-seed commensals and feed them, improving stool form, immune markers, and motility in IBS and dysbiosis.
  • Glutamine and zinc carnosine → restore epithelial energy and mucosal structure, lowering antigen translocation (Ueda et al., 2007).
  • DIM/I3C → steer estrogen toward 2-OH and away from 4-OH/16-OH, lowering quinone burden and proliferative signaling (Bradlow, 2019; Kabat et al., 2006).
  • Methylation support → completes detox of catechol estrogens and protects DNA via COMT and related pathways.
  • Calcium D-glucarate → promotes glucuronidation and reduces beta-glucuronidase-driven recirculation.
  • D3–K2–A with magnesium → improves immune modulation and calcium trafficking, protecting bone and vasculature (Beulens et al., 2013; Pilz et al., 2019; Mitchell et al., 2022).
  • Iodine with selenium → restores thyroid hormone synthesis while protecting against H2O2-driven oxidative damage; supports deiodinases (Gärtner et al., 2002; Zimmermann, 2003).
  • Shilajit → raises free testosterone and supports mitochondrial function, smoothing symptom curves across pellet cycles (Pandit et al., 2016).
  • Chiropractic-informed autonomic care → increases vagal tone and reduces nociception, lowering cytokines and improving motility, digestion, and sleep (Tracey, 2002; Cryan & Dinan, 2015).

Putting It All Together: A Gut-First, Whole-Person Strategy

When we respect the body’s systems biology, we see why a gut-first strategy with autonomic balance makes hormones and thyroid therapies work predictably. By:

  • Sealing the barrier and raising SCFAs,
  • Lowering LPS and cytokines,
  • Steering estrogen metabolism toward safer pathways with DIM/I3C and ensuring excretion with calcium D-glucarate, fiber, and bile flow,
  • Optimizing vitamin D3–K2–A with magnesium and carefully integrating iodine–selenium for thyroid,
  • Supporting bioavailable androgens with shilajit when appropriate,
  • And integrating chiropractic care to normalize autonomic tone and movement.

We consistently move patients from symptom management to durable health. This approach is practical, measurable, and aligned with modern, evidence-based methods. In my experience, it is also the fastest, safest way to feel well and stay well.

References


SEO tags: gut health, dysbiosis, intestinal permeability, LPS, SCFAs, estrobolome, beta-glucuronidase, estrogen metabolism, DIM, I3C, calcium D-glucarate, vitamin D3, vitamin K2, vitamin A, iodine, selenium, Hashimoto’s, thyroid conversion, Akkermansia muciniphila, shilajit, free testosterone, HRT pellets, integrative chiropractic care, vagal tone, HRV, functional medicine, microbiome sequencing, metabolomics, NF-κB, TLR4, COMT, Nrf2

Gut Health and Hormone Balance Treatment

Gut Health and Hormone Balance Treatment

Gut Health and Hormone Balance Treatment

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the science and practice of optimizing hormones by treating the gut–liver–hormone axis and reinforcing micronutrient and mitochondrial foundations. I explain how dysbiosis, intestinal permeability, and microbial enzymes like beta-glucuronidase reshape estrogen metabolism and influence conditions such as PCOS, endometriosis, and autoimmunity, and how lipopolysaccharide (LPS) and short-chain fatty acids (SCFAs) affect insulin sensitivity, mood, and inflammation. I translate current research on vitamin D, K2, iodine, selenium, methylated B vitamins, DIM, and shilajit into clinic-ready protocols, and I show where integrative chiropractic care fits by supporting vagal tone, motility, neuromusculoskeletal dynamics, and autonomic balance. You will find practical frameworks, dosing concepts, lab-monitoring advice, and rationale for each intervention, with citations to leading researchers.

Why Hormones Are Microbiome-Dependent: The Gut–Liver–Hormone Axis

When I first connected hormone symptoms to gut physiology, I saw a pattern: many “hormone” problems began as microbiome and barrier problems. The gut microbiome—a complex community of bacteria, viruses, fungi, and archaea—regulates digestion, immune tolerance, barrier integrity, and the enterohepatic circulation that clears estrogens. From the earliest studies linking metabolic endotoxemia to insulin resistance, it has become clear that LPS-driven inflammation can disrupt cardiometabolic and reproductive health (Cani et al., 2007).

  • When the microbiome is balanced, commensals generate SCFAs (notably butyrate) that nourish colonocytes, tighten junctions, and reduce inflammatory signaling.
  • When dysbiosis develops, beta-glucuronidase-producing taxa expand, and LPS permeates, amplifying NF-κB cytokine cascades that alter hormone receptors, hepatic detoxification, and insulin signaling (Fasano, 2012; Slyepchenko et al., 2017).

Clinically, if you manage estrogen symptoms, insulin resistance, or autoimmune patterns, you are managing the microbiome—whether you realize it or not.

Dysbiosis and Leaky Gut Explained: Distinct Problems that Reinforce Each Other

Two related but distinct issues commonly coexist:

  • Dysbiosis: A shift away from beneficial microbes, with loss of diversity and expansion of pathobionts. Consequences include increased LPS, altered bile acid signaling, and elevated beta-glucuronidase.
  • Leaky gut (increased intestinal permeability): Disruption of tight junction proteins (occludin, claudins, ZO-1) allows antigens and endotoxins to enter circulation, thereby increasing systemic inflammation and immune activation (Fasano, 2012).

Why that matters for hormones:

  • LPS activates TLR4–NF-κB, increasing TNF-α, IL-1β, and IL-6—cytokines that reduce insulin signaling and alter steroid hormone receptor function (Cani et al., 2007).
  • Permeability increases immune load and oxidative stress, thereby consuming methyl donors and glutathione needed for safe phase II detox (methylation, glucuronidation, sulfation) of estrogens.

I screen for these drivers whenever patients report PMS, heavy cycles, PCOS features, endometriosis pain, acne or hair loss, mood changes, fatigue, or autoimmune flares. Correcting the gut often increases the safety and efficacy of hormone therapy.

Estrogen Metabolism 101: Enterohepatic Circulation and the Estrobolome

The liver metabolizes estrogens via phase I hydroxylation (CYP1A1, CYP1B1) and phase II conjugation (COMT methylation, glucuronidation, sulfation). Conjugated metabolites pass into bile and should be excreted. In dysbiosis, microbial beta-glucuronidase deconjugates these estrogens, promoting reabsorption and recirculation—the biochemical basis of “estrogen dominance,” even with careful dosing (Plottel & Blaser, 2011).

  • 2-hydroxylation generally produces less proliferative metabolites.
  • 4- and 16α-hydroxylation yield more proliferative or potentially genotoxic metabolites if methylation and conjugation are suboptimal.

In complex cases or when there is a family history of estrogen-dependent cancers, I consider urinary metabolite testing to map pathways and guide targeted support.

PCOS, Endometriosis, and Autoimmunity: What the Microbiome Adds

Recent studies sharpen the microbiome’s role:

  • PCOS: Dysbiosis with fewer SCFA producers and higher LPS correlates with insulin resistance, hyperandrogenism, and impaired GLP-1 signaling (Lindheim et al., 2017; Qi et al., 2019). Restoring butyrate producers improves metabolic tone.
  • Endometriosis: Altered microbiota, increased permeability, and immune activation correlate with symptom severity. Increased beta-glucuronidase raises estrogen recirculation that can exacerbate lesions and pain (Chen et al., 2017; Jiang et al., 2017).
  • Autoimmunity: Barrier dysfunction and loss of tolerogenic species permit pathobiont translocation and molecular mimicry, priming autoimmune activity (Manfredo Vieira et al., 2018).

Clinical translation: Addressing the gut can reduce hormone dosing requirements, expand the therapeutic window, and stabilize mood, sleep, and metabolism.

The Simple Question with Big Impact: Are You Pooping Daily?

I ask every patient: “Do you have a daily bowel movement?”

  • Estrogen metabolites exit via bile and stool. Constipation increases residence time, giving beta-glucuronidase more opportunity to deconjugate and recirculate estrogens.
  • Correcting bowel habits is a core risk-reduction strategy for estrogen-driven conditions.

Practical steps I use:

  • Increase hydration and electrolytes.
  • Ramp fiber to 25–35 g/day; add PHGG (partially hydrolyzed guar gum) 4–6 g/day for low-bloat prebiotic support.
  • Add magnesium glycinate or citrate at night for stool regularity and sleep.
  • Encourage postprandial walks and vagal toning (slow exhale breathing, humming).

A 3-by-3 Framework for Gut Repair: Remove, Replace, Repair

To keep things doable, I use a 3-by-3 approach:

  1. Remove/Reduce Irritants
  • Clean up the diet: favor whole foods; limit alcohol, ultra-processed items, added sugars; consider a gluten-light or gluten-free trial for sensitive individuals.
  • Medication review: minimize NSAIDs and PPI overuse when clinically safe.
  • Stress load: hard-wire breath work, walks, and sleep hygiene.
  1. Replace and Restore
  • Fiber and prebiotics: 25–35 g/day total fiber; add PHGG for gentle SCFA support.
  • Probiotics: multi-strain Lactobacillus and Bifidobacterium blends (e.g., L. rhamnosus GG, B. lactis) for barrier and immune balance.
  • Digestive support: bitters and meal hygiene for hypochlorhydria/slow motility; phosphatidylcholine and balanced fats for bile flow.
  1. Repair and Rebalance
  • Barrier repair: L-glutamine 5 g/day, zinc carnosine, N-acetyl-D-glucosamine, omega-3s as indicated.
  • Inflammation control: Berberine for dysbiosis-associated endotoxemia; curcumin and quercetin for NF-κB calming.
  • Lifestyle anchors: 150 minutes/week activity; 10-minute post-meal walks; consistent 7–9 hours of sleep.

Why this approach works:

  • Prebiotics increase SCFAs, reinforce tight junctions, and support T-regs via HDAC inhibition.
  • Probiotics competitively inhibit pathobionts, reduce beta-glucuronidase activity, and enhance mucosal IgA.
  • L-glutamine fuels enterocytes and accelerates barrier recovery.
  • Berberine improves the microbial balance and activates AMPK to improve insulin sensitivity.

Nutrient Foundations for Receptor-Level Hormone Action: D, K2, A, Magnesium, Iodine, Selenium, and Methylation

I frequently see patients with robust serum hormones but poor tissue effects. The missing link is often receptor signaling, cofactors, and membranes.

  • Vitamin D3 behaves like a secosteroid hormone that modulates transcription through the VDR. Low vitamin D is associated with all-cause and cardiovascular mortality and can blunt androgen signaling even when total testosterone appears normal (Pilz et al., 2011; Holick, 2017).
  • Magnesium is a cofactor for D activation (25- and 1α-hydroxylases); deficiency dampens VDR signaling (Rosanoff et al., 2016).
  • Vitamin K2 directs calcium into bone and away from soft tissues by activating matrix Gla protein and osteocalcin; it complements D to protect vessels and build bone (Schurgers & Vermeer, 2000; Beulens et al., 2013).
  • Vitamin A supports epithelial integrity, immune balance, and nuclear receptor synergy with vitamin D.

I often use an ADK formula (D3 with K2 and A) alongside magnesium to safely improve receptor-mediated effects, while monitoring 25(OH)D, calcium, and PTH (Rosen et al., 2012).

Thyroid resilience: iodine and selenium synergy

  • Iodine is essential for T4/T3 synthesis, but safe utilization depends on selenium-dependent enzymes (glutathione peroxidases, thioredoxin reductases) to quench the H2O2 generated during iodide organification (Ventura et al., 2017).
  • Inadequate selenium increases oxidative stress at the thyroid, raising the risk of autoimmunity when iodine intake rises (Gartner & Gasnier, 2003).
  • I pair iodine (200–400 mcg) with selenium (100–200 mcg selenomethionine) and often zinc (10–30 mg), titrated to labs and symptoms (Zimmermann & Boelaert, 2015).

Methylation for estrogen safety

  • Methylated B vitamins—methylfolate and methylcobalamin—support COMT-mediated methylation of catechol estrogens, reducing genotoxic stress and stabilizing phase II clearance.

These micronutrients are the bedrock that allows hormones to “dock” and trigger healthy cellular responses.

DIM and Estrogen Metabolites: Steering Toward Safer Pathways

Diindolylmethane (DIM) shifts estrogen metabolism toward 2-hydroxylation and away from 16α- and 4-hydroxylation pathways associated with proliferative and genotoxic risk (Zeligs et al., 2006; Reed et al., 2006). Preclinical studies suggest that DIM may also upregulate BRCA1 signaling and promote apoptosis in cancer cell lines (Fan et al., 2009; Li et al., 2010).

How I apply it:

  • Women with estrogen-dominant symptoms or unfavorable metabolite profiles: 150–300 mg/day, adjusted to labs and tolerance.
  • Men with prostate risk or aromatization-driven symptoms: 300–600 mg/day, personalized.
  • I pair DIM with omega-3s, iodine/selenium, and fiber/probiotics to support the entire estrobolome–liver–stool axis.

Rationale: By changing metabolite balance and supporting conjugation, DIM decreases receptor overstimulation and DNA-adduct risk while improving symptom stability.

Shilajit for Free Testosterone and Mitochondrial Support

Some patients—particularly young males—present with high total testosterone but low free testosterone and low vitality. Shilajit, a purified, fulvic-acid–rich resin, has randomized data showing increases in total (~31%), free (~51%), and DHT (~37%) over ~90 days at 250 mg twice daily (Pandit et al., 2016). Mechanisms likely include improved mitochondrial function, nutrient transport, and hypothalamic–pituitary–gonadal signaling.

How I use it:

  • In those seeking endogenous support without exogenous hormones, I combine shilajit with vitamin D, magnesium, zinc, B12, and iodine/selenium when indicated, then track changes in free T, SHBG, energy, and body composition.

Why this works: Enhancing mitochondrial ATP and cofactor availability raises tissue responsiveness; changes in binding dynamics can increase the bioactive fraction without pushing total testosterone to excessive levels.

Vitamin D as a Systemic Modulator: Barrier, Immunity, and Receptors

I routinely optimize vitamin D because it acts at the intersection of immunity, barrier integrity, and endocrine signaling. Observational data tie suboptimal 25(OH)D to higher risks across diseases (Bouillon et al., 2019). Mechanistically, D supports tight junction proteins, cathelicidin, and endocrine receptor sensitivity. Clinically, many patients feel “stuck” until D is restored to an optimal range; I often target 60–80 ng/mL with appropriate monitoring to avoid hypercalcemia (Holick, 2017; Rosen et al., 2012).

Integrative Chiropractic Care: The Neuroimmune–Endocrine Interface

As a chiropractor and nurse practitioner, I see daily how autonomic balance, fascial mobility, and pain modulation determine whether patients can absorb nutrients, move consistently, and sleep well—foundations for endocrine success.

  • Vagal tone and motility: Gentle spinal and cervical adjustments can influence autonomic balance, improving gut motility, secretory IgA, and anti-inflammatory vagal pathways. Patients with low vagal tone present with constipation, bloating, and poor stress resilience.
  • Fascia and diaphragm: Thoracolumbar fascial restrictions and diaphragmatic stiffness impair breathing mechanics and lymphatic flow, promoting sympathetic overdrive. Mobility restores circulation and reduces pain.
  • Pain reduction without NSAIDs: Lowering nociception decreases cortisol and protects the mucosa from NSAID-induced permeability.
  • Behavioral activation: When pain decreases, patients walk, train, and sleep—activities that increase SCFAs, improve insulin sensitivity, and stabilize mood.

These neurophysiologic effects align with published observations on autonomic modulation and musculoskeletal care (Pickar, 2002; Lehman et al., 2012) and help nutrition and endocrine strategies “stick” in daily life.

For examples of how we operationalize this, see my resources at Chiromed and my professional updates on LinkedIn.

A Phased, Clinic-Ready Protocol for Gut and Hormone Optimization

I layer care to build momentum and safety.

Phase 1: Stabilize and Build Trust (Weeks 0–4)

  • Ensure daily bowel movements; add PHGG, hydration, and magnesium as needed.
  • Start a multi-strain probiotic (Lactobacillus + Bifidobacterium).
  • Begin vitamin D3 with K2 and magnesium; consider ADK formulations.
  • Introduce walks after meals and fixed sleep schedules.
  • Provide chiropractic adjustments and diaphragmatic work to normalize autonomics and reduce pain.
  • Baseline labs: CBC, CMP, 25(OH)D, calcium, PTH, thyroid panel (TSH, free T4/T3), thyroid antibodies as needed, ferritin, B12, folate, magnesium, zinc, selenium, CRP, fasting insulin/glucose, lipid profile, estradiol, total and free testosterone, SHBG.

Phase 2: Targeted Gut Repair and Hormone Pathways (Weeks 4–12)

  • Add L-glutamine 5 g/day for barrier support when indicated.
  • Short berberine course for endotoxemia/dysbiosis; replete with probiotics.
  • Add DIM if clinical or metabolite data show proliferative pathways.
  • Start a methylated B complex to support COMT and phase II detox.
  • Maintain chiropractic care cadence for autonomic and biomechanical resilience.

Phase 3: Personalize, Monitor, and Maintain (Months 3+)

  • Reassess symptoms, bowel habits, and targeted labs; titrate to the lowest effective doses.
  • Reinforce lifestyle anchors: fiber intake, movement, sleep, and stress practices.
  • Schedule periodic tune-ups for the spine, fascia, and breath mechanics to sustain vagal tone and support recovery.

This sequencing respects physiology and behavior: patients feel better first, then commit to more significant changes—resulting in better adherence and durable outcomes.

Special Focus: PCOS and Endometriosis

PCOS

  • Emphasize insulin sensitization through fiber, postprandial walks, resistance training, and, where appropriate, berberine.
  • Reduce LPS: probiotics, polyphenols, and barrier repair to lower endotoxemia.
  • Consider inositols for ovulatory support alongside gut therapy.
  • Monitor androgenic symptoms as gut protocols progress; improvements often track with better bile acid and SCFA signaling.

Endometriosis

  • Reduce beta-glucuronidase pressure via probiotics and fiber to limit estrogen recirculation.
  • Calm neuroimmune inflammation with omega-3s, curcumin, and sleep optimization.
  • Use gentle movement and manual therapy to address pelvic floor tension and diaphragm mobility; sympathetic downshift reduces pain tone.
  • Coordinate with gynecology; gut protocols augment, not replace, indicated care.

Case Reflection: High Total Testosterone, Low Vitality

I saw an 18–19-year-old male with low mood, low energy, weight gain, and “low-T” symptoms. His total testosterone was ~900 ng/dL—clearly not low. What we found: very low vitamin D, low B12, and signs of micronutrient insufficiency. I started a robust B-complex, ADK (D3 + K2 + A), iodine paired with selenium, and magnesium. At follow-up, his mother said, “He’s a totally different person.” Energy, mood, and cognition improved, and multiple medications were discontinued. The physiology: hormones were present, but receptor signaling and cellular machinery were underpowered. Restoring micronutrients enabled the hormones to “work.”

In other young men with high total but low free testosterone, I have added shilajit and structured resistance training. Free fractions improved, and vitality followed—without pushing total testosterone into excess.

Safety, Lab Monitoring, and Personalization

  • Monitor: 25(OH)D, calcium, PTH for vitamin D repletion; thyroid panel and antibodies for iodine–selenium strategies; ferritin, B12, folate, magnesium, zinc, selenium, CRP for micronutrient and inflammatory status; sex hormones including free testosterone and SHBG.
  • Adjust doses to labs and symptoms. If vitamin D stays low despite oral dosing, assess bile flow, fat absorption, and adherence; consider supervised loading.
  • Cautions:
    • Vitamin A: avoid hypervitaminosis; use caution in pregnancy.
    • Iodine: go slowly with autonomous nodules or hyperthyroidism; collaborate with endocrinology.
    • Zinc: long-term high dosing can lower copper; keep the balance.
    • DIM and shilajit: use third-party-tested products; personalize the dose.
    • Berberine: short targeted courses; watch for GI sensitivity and drug interactions.

How Integrative Chiropractic Care Complements Endocrine and Gut Strategies

Mechanistically, chiropractic-informed care bridges biochemistry and behavior:

  • Reduces nociception and sympathetic overdrive, lowering cortisol drag on thyroid conversion and gonadal axes (Lehman et al., 2012).
  • Improves respiratory mechanics and fascial glide, supporting lymphatic flow, nutrient delivery, and waste clearance.
  • Enhances vagal tone, supporting motility, secretory IgA, and peristalsis—foundations for microbiome stability.
  • Facilitates movement prescriptions (resistance training, mobility, aerobic intervals) that reduce aromatase activity, improve insulin sensitivity, and raise androgen receptor density.

In my practice, patients combining endocrine protocols with spinal–fascial optimization report better sleep, steadier energy, more predictable lab trajectories, and lower required doses—an elegant synergy of systems biology and hands-on care. Explore our integrative approach at Chiromed and my professional notes on LinkedIn.

Why Each Technique Matters: Systems Biology Rationale

  • Fiber/PHGG: Feeds SCFA producers, tightens junctions, and supports GLP-1 signaling.
  • Probiotics: Reduce beta-glucuronidase, improve barrier integrity, and temper endotoxemia.
  • L-glutamine: Primary fuel for enterocytes; accelerates epithelial repair.
  • Berberine: Reshapes the gut microbiota, lowers LPS levels, and activates AMPK to improve insulin sensitivity.
  • DIM: Steers estrogen toward 2-hydroxylation, lowering proliferative load.
  • Methylated B vitamins: Enable COMT activity and conjugation; reduce genotoxicity of catechol estrogens.
  • Vitamin D + K2 + A + Mg: Align receptor signaling and calcium kinetics; protect vessels and bone.
  • Iodine + selenium: Support thyroid synthesis while detoxifying H2O2 to prevent autoimmune escalation.
  • Shilajit: Enhances endogenous androgens via mitochondrial and HPG-axis support.
  • Chiropractic care: Normalizes autonomic function, reduces pain, and supports movement habits that sustain microbiome and endocrine gains.

Each intervention nudges a different lever; together, they realign the system.

Clinical Observations from Practice

Across patient cohorts at my clinic, we see reproducible patterns:

  • Resolving constipation reduces PMS and “estrogen rollercoaster” symptoms within weeks.
  • Regular adjustments correlate with improved sleep and stress tolerance, enabling consistent training and meal timing that benefit the microbiome.
  • Vitamin D optimization often coincides with improved mood, less joint pain, and better responses to both gut and hormone protocols.

These observations are consistent with the mechanistic and clinical literature, reinforcing the rationale for why foundational steps deliver outsized results. For more, visit Chiromed and my LinkedIn updates.

References

Hormone Balance, Iron Health, and Contraceptive Care

Hormone Balance, Iron Health, and Contraceptive Care

Hormone Balance, Iron Health, and Contraceptive Care

Abstract

As a clinician blending chiropractic, functional medicine, and advanced nursing practice, I see how hormone physiology, micronutrients, and systems biology converge to shape health, recovery, and resilience. In this educational post, I walk you through practical, evidence-informed strategies for evaluating iron deficiency and ferritin; interpreting cortisol and thyroid dynamics; selecting and titrating progesterone, estrogen, and testosterone in complex scenarios (PCOS, IUD selection, male fertility and TRT rebound, TIA and stroke risk considerations, endometriosis, and menopause); and understanding the nuanced oncology context around DCIS and hormone receptors. I also explain how integrative chiropractic care fits into these plans by balancing the nervous and hormone systems, improving body functions, and supporting health through hands-on therapy, exercise, sleep, and diet. Throughout, I present current literature from leading researchers and add real-world observations from my practice (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST) to help you translate physiology into precise, patient-centered care.

Foundations Of Identity In Care Planning And Clinical Context

  • Why this matters: Many patients navigate multiple identities—athlete and parent, caregiver and executive, patient and advocate. Clinically, multiple identities often map onto competing physiological stresses: sleep compression, high allostatic load, and variable patterns of nutrition and movement. Recognizing these factors is the first step in aligning care with lived realities.
  • Integrative chiropractic fit: In my clinic, identity-informed care plans build adherence. When I address spine and fascial mechanics and autonomic balance with targeted manual therapy, patients experience immediate relief that reinforces engagement with longer-term hormonal and nutritional strategies. Clinically, I see better follow-through on lab timing, supplement dosing, and structured movement when the body feels aligned and capable.

Iron Physiology, Ferritin, And Root-Cause Mapping

Understanding iron requires separating storage, transport, and utilization:

  • Key biomarkers:
    • Serum ferritin: a proxy for iron stores but an acute-phase reactant—elevates with inflammation (hepcidin-mediated sequestration).
    • Serum iron and transferrin/TIBC: reflect circulating iron and binding capacity.
    • Transferrin saturation (%): often the most useful single index with ferritin.
    • Reticulocyte hemoglobin (CHr) and soluble transferrin receptor (sTfR): help distinguish true deficiency from anemia of inflammation.

Physiology in brief:

  • The liver peptide hepcidin governs iron absorption and release from macrophages. Inflammation increases hepcidin, lowering absorption and locking iron in stores—low iron availability with normal/high ferritin.
  • True iron deficiency presents with low ferritin, low iron, high TIBC, and low transferrin saturation. Anemia of chronic inflammation shows low iron, low/normal TIBC, and normal/high ferritin.

Why patients stay iron-deficient:

  • Decreased intake or high phytate/polyphenol diets limit absorption.
  • Malabsorption: hypochlorhydria, celiac spectrum, SIBO, gastric bypass.
  • Losses: heavy menses, GI blood loss, frequent phlebotomy, and endurance training.
  • Special populations: neonates can experience early postnatal physiologic shifts; in adults, postpartum, post-surgery, and endurance athletes require tailored screening.

Clinical approach I use:

  • Map the cause: hydration status, GI absorption, occult bleeding (including fecal immunochemical testing), menstrual history, PPI use, celiac panel if indicated, and inflammatory markers (CRP, ESR).
  • Replace iron physiologically: I favor alternate-day oral iron to align with hepcidin’s diurnal rhythm and reduce GI side effects, supported by recent randomized trials showing improved absorption with every-other-day dosing (Stoffel et al., 2017). Using ferrous bisglycinate or heme iron polypeptide can enhance tolerance.
  • Repletion targets: Bring ferritin to symptom-relief thresholds (often 50–100 ng/mL for fatigue and hair loss), then sustain. Monitor hemoglobin, ferritin, and transferrin saturation every 8–12 weeks during repletion.

Integrative chiropractic fit:

  • Manual therapies that improve thoracic mobility and diaphragmatic excursion enhance vagal tone and GI perfusion, supporting absorption. Coaching on timing iron away from calcium and with vitamin C-rich foods further increases uptake. I often see faster symptom improvement when we combine postural breathing retraining and gentle aerobic conditioning with iron repletion.

Hormonal IUDs, Progestin Families, And Thrombotic Risk

Not all progestins are the same. Families differ in androgenicity and thrombotic risk:

  • Levonorgestrel (Mirena and similar): primarily a local uterine effect with low systemic levels; robust evidence supports low VTE risk compared with systemic progestins (ACOG, 2022).
  • Norethindrone: different side-effect profile and hepatic metabolism from progesterone; systemic exposure carries VTE risk similar to combined oral contraceptives when used in combination with estrogen.
  • Biologic progesterone (micronized) differs from synthetic progestins in receptor activity and in metabolites (e.g., allopregnanolone), which influence mood and sedation.

Why are Levonorgestrel IUDs often well tolerated?

  • The local endometrial action results in reduced systemic exposure, decreased bleeding, and endometrial protection, with a favorable safety profile. This is one reason neurosurgical and periprocedural contexts prefer local or targeted effects when feasible—namely, to reduce systemic adverse events.

Integrative chiropractic fit:

  • Pelvic floor integration matters. I routinely coordinate pelvic floor assessment and diaphragmatic mechanics with IUD choice. Improved lumbopelvic control and reduced sympathetic arousal can decrease cramping and improve IUD tolerance.

Progesterone Strategy In Sensitive Patients And PCOS Contexts

Clinical problem: Some patients with PCOS or HPA dysregulation report mood lability with oral progesterone.

Physiology:

  • Oral micronized progesterone converts to allopregnanolone, a positive allosteric modulator of GABA-A receptors. In most, this is anxiolytic; in a sensitive minority, neurosteroid fluctuations can provoke dysphoria.
  • Sublingual and transdermal routes bypass some first-pass metabolism, altering metabolite profiles and CNS effects.

My approach:

  • Start with a low-dose oral micronized progesterone (e.g., 100 mg qHS) to promote sleep and provide endometrial protection. If not tolerated:
    • Switch to a sublingual troche at half the equivalent oral dose (sublingual tends to achieve higher bioavailability; clinically, 100 mg sublingual can approximate 200 mg oral).
    • Quartering a 200 mg troche yields ~50 mg sublingual aliquots for fine titration.
  • Why this works: By modulating route and dose, we can smooth neurosteroid peaks, reduce daytime sedation, and maintain endometrial safety when used with estrogen.
  • For PCOS on androgen therapy: Balance is critical. A small androgen signal can be synergistic for mood, energy, and libido, but carefully calibrate it with estrogen and progesterone to avoid endometrial hyperplasia, acne, or dyslipidemia. Track SHBG, lipids, and insulin resistance.

Integrative chiropractic fit:

  • Autonomic stabilization through cervical-thoracic manipulation and breathing retraining reduces adrenergic drive that often amplifies progesterone sensitivity. When we address sleep quality and nocturnal bruxism with TMJ and cervical work, I see smoother adaptation to progesterone in practice.

Cortisol Testing: Salivary Profiles Versus Serum

Why measure multiple points:

  • Cortisol follows a diurnal curve: a peak within 30–45 minutes after waking (CAR) and a gradual decline throughout the day. A single AM serum cortisol measurement may miss dysregulated patterns.
  • A 4–5-point salivary cortisol series captures CAR, midday, afternoon, and evening levels—useful for sleep disturbances, burnout, and suspected HPA axis alterations (O’Connor et al., 2021).

When I choose each:

  • For pattern analysis and sleep complaints: multi-point salivary cortisol.
  • For adrenal insufficiency screening or acute illness: AM serum cortisol ± ACTH stimulation.

Integrative chiropractic fit:

  • Chiropractic care and breath-led movement can normalize autonomic balance, often flattening hyper-adrenergic spikes that correlate with evening cortisol elevations. I pair care with light-in-the-morning, dim-in-the-evening routines to reinforce circadian rhythms.

Male Fertility, Clomiphene, And TRT Rebound

In men in their 20s–30s with low testosterone who want fertility:

  • I avoid long-term estrogen receptor blockade. Short courses of clomiphene citrate (3–6 months) can increase LH/FSH levels, thereby increasing endogenous testosterone and sperm counts (Helo et al., 2017). It is not for indefinite use due to visual and mood risks and potential lipid changes.
  • Off peptides/TRT: I use timed clomiphene or enclomiphene to accelerate spermatogenesis while lifestyle and nutrition restore HPG axis tone.
  • Foundational first: For younger men, I prioritize diet quality, sleep, resistance training, weight normalization, and correcting micronutrient levels (vitamin D, B-complex, zinc, magnesium). I frequently see total testosterone rise from low 300s into 700–800 ng/dL over 6–9 months with lifestyle adherence.

Integrative chiropractic fit:

  • Restoring thoracic mobility and rib mechanics improves breathing efficiency and training capacity; correcting lumbopelvic mechanics reduces systemic inflammation from overuse. The autonomic shift toward parasympathetic tone deepens sleep, which is crucial for nocturnal gonadal hormone secretion.

DCIS, Hormone Receptors, And Personalized Risk-Benefit

Terminology and nuance:

  • Ductal carcinoma in situ (DCIS) is a noninvasive neoplastic process confined to the ducts. While often called “stage 0 breast cancer,” it lacks stromal invasion; management varies widely.
  • Receptor positivity (ER, PR, AR) indicates ligand-responsive pathways. Receptors are normal cellular features; their presence does not inherently mandate systemic suppression in all contexts.

Standard-of-care realities:

  • Many oncology pathways default to anti-estrogen strategies (e.g., tamoxifen) in receptor-positive lesions. My stance: align with oncology for invasive disease or recent treatment, but individualize for remote history or post-mastectomy scenarios, considering symptom burden and quality-of-life outcomes (Early Breast Cancer Trialists’ Collaborative Group, 2011; Cuzick et al., 2011).

Clinical reasoning:

  • In a patient decades post-bilateral mastectomy with no residual breast tissue, the theoretical tissue-specific risk is different from that of a patient 6 months post-lumpectomy still on adjuvant therapy. I weigh the systemic benefits of estrogen (bone, vasomotor stability, cognition, urogenital health) against realistic tissue risks, use shared decision-making, and document this via informed consent.

Integrative chiropractic fit:

  • Many of these patients struggle with pain, sleep disruption, and deconditioning. Postural restoration, scar mobility work, and gentle strengthening reduce sympathetic load, allowing lower-dose hormone regimens to achieve symptom control.

TIA, Stroke Risk, And Sex Hormones

Historical concern has linked estrogen to stroke risk, particularly in oral forms and in older trials with higher doses started late after menopause. The modern view:

  • Route matters: Transdermal estradiol has a more favorable thrombotic profile than oral estradiol because it bypasses first-pass hepatic effects on clotting factors (Canonico et al., 2016).
  • Testosterone does not require routine discontinuation after TIA in carefully selected women and men; the focus is on global vascular risk management (blood pressure, glycemic load, sleep apnea, hematocrit monitoring in men on TRT).
  • In patients who received pellet therapy near a TIA event, I evaluate vascular risks comprehensively. Anecdotally and mechanistically, sustained androgen levels do not necessarily precipitate cerebrovascular events; confounding factors (dehydration, arrhythmia, migraine with aura, hypercoagulable states) must be assessed.

Why integrative care helps:

  • Cervical and upper thoracic biomechanical dysfunction can aggravate headaches and sympathetic tone. By improving cervical proprioception, rib mechanics, and breathing patterns, I observe reduced migraine frequency and better control of blood pressure variability, which complements hormone prudence.

Immediate-Release Versus Extended-Release In Symptom Relief

In my practice, I often choose immediate-release formulations when seeking neurosensory benefits (e.g., anxiolysis, sleep initiation) from agents with CNS effects because:

  • Faster onset can more directly target symptom windows (e.g., bedtime).
  • It allows finer titration and identification of dose-response relationships.

When I choose extended-release:

  • For hormones or agents where steady state is crucial to avoid peaks/valleys, or when side effects are dose-peak-related. Personalization is key.

Endometriosis And Menopause: Progesterone Essentials

Key principles:

  • In menopausal women with a history of endometriosis on estrogen therapy, I favor co-prescribing progesterone even without a uterus. Rationale: ectopic endometrial implants may persist extrauterine and remain hormonally responsive. Progesterone has anti-proliferative effects on endometrial tissue and may reduce the risk of malignant transformation (Vercellini et al., 2014).

Testosterone and endometriosis:

  • Testosterone generally has neutral direct effects on endometriotic lesions; symptom modulation is more indirect (energy, libido, mood). I monitor acne, hair growth, and lipids.

Integrative chiropractic fit:

  • Pelvic and lumbosacral mechanics impact pelvic congestion and pain. Coordinated pelvic floor therapy, sacroiliac mobilization, and graded movement often reduce pain and allow lower estrogen doses with better function.

Thyroid Physiology: T4, Reverse T3, And Desiccated Thyroid

Why do some patients struggle with isolated levothyroxine?

  • T4 to T3 conversion is context-dependent: inflammation (IL-6), chronic stress (cortisol), and caloric restriction increase deiodinase 3, generating reverse T3 as a protective brake.
  • Bolus T4 dosing can, in sensitive patients, drive higher reverse T3 and leave tissues relatively hypothyroid despite normal TSH and free T4.

When I consider combination therapy:

  • If free T3 is low-normal with symptoms and reverse T3 is elevated, a trial of T3 addition or desiccated thyroid can be considered, monitoring HR, BP, and symptoms.
  • Desiccated thyroid includes T1/T2 in addition to T4/T3; while evidence is mixed, some patients report improved well-being (Hoang et al., 2013). The physiologic appeal is a more native ratio of iodothyronines.

Dosing logic:

  • Keep total T3 exposure rational (avoid overtreatment). Many patients do well at conservative desiccated doses (e.g., 60–120 mg with split dosing) or modest liothyronine add-on.
  • If reverse T3 is persistently high, look upstream: inflammation, gut dysbiosis, iron deficiency, sleep apnea, and medications. Raising the dose alone rarely fixes a conversion problem.

Integrative chiropractic fit:

  • By improving sleep quality and decreasing pain, we reduce cortisol and catecholamine tone that can impair peripheral conversion. I frequently pair thyroid adjustments with gut-directed nutrition, iron repletion, and aerobic conditioning to normalize deiodinase activity.

Estriol, Estradiol, And Skin Or Urogenital Targets

  • Estriol (E3) is a weaker estrogen with higher affinity for ER-beta, associated with urothelial and skin benefits and a theoretical reduced proliferative risk profile (Labrie et al., 2017).
  • On its own, estriol is often too weak for vasomotor symptoms; patients may continue to have hot flashes with estriol pellets or low-dose creams.
  • Bi-est combinations (estriol + estradiol) can increase serum estradiol; monitor for bleeding. For vulvovaginal atrophy, low-dose local estradiol or estriol is typically effective with minimal systemic absorption.

Integrative chiropractic fit:

  • Postural improvement, hip mobility, and pelvic floor coordination augment local tissue perfusion and sexual function. Patients often need lower topical doses when musculoskeletal contributors are addressed.

TRT In Men: Hematocrit, Estradiol, And Practical Monitoring

For men on testosterone injections who feel great but develop high hematocrit:

  • Tactics include dose and interval adjustments, switching to transdermal forms, therapeutic phlebotomy if indicated, and addressing sleep apnea, hydration, and iron stores.
  • I monitor hematocrit, estradiol, SHBG, PSA, lipids, and blood pressure. Aromatization to estradiol can be beneficial for bone and mood; I avoid reflexive overuse of aromatase inhibitors and instead optimize dose and lifestyle.

Integrative chiropractic fit:

  • Correcting thoracic outlet and rib mechanics can support breathing and reduce sleep apnea severity alongside weight loss—a key driver of safer TRT hematology.

Gut-First When Thyroid Therapy “Should Work” But Doesn’t

When free T3 is approaching the target (e.g., 4.0+ pg/mL), yet patients still feel unwell:

  • I reassess gut health: dysbiosis, SIBO, post-viral inflammation, food sensitivities. The gut-liver axis modulates thyroid hormone metabolism and immune cross-talk, particularly in Hashimoto’s.
  • I commonly see symptom breakthroughs after:
    • Eliminating trigger foods (gluten in celiac spectrum; individualized otherwise),
    • Repleting selenium, zinc, iron, vitamin D, B12, and magnesium, and
    • Restoring sleep and movement rhythm.

Integrative chiropractic fit:

  • Vagal stimulation through breathing and thoracic mobilization, coupled with graded walking and core stability, improves motility and lowers systemic inflammatory tone.

Clinical Vignettes And Observations From Practice

  • Ferritin plateaus despite oral iron: With alternating-day dosing with vitamin C, stopping concurrent calcium, checking for H. pylori and celiac markers, and adding diaphragmatic breathing drills for reflux, patients often see ferritin rise to 60–100 ng/mL within 12–16 weeks. Combining manual therapy to reduce costal margin restriction improved tolerance of iron and reduced GERD complaints in my clinic.
  • Progesterone intolerance in perimenopause: Switching from 200 mg oral nightly to 50–100 mg sublingual in divided evening doses, plus cervical release and sleep hygiene, stabilized mood and sleep within two cycles for most sensitive patients.
  • Young male with low T and fatigue: A 9-month plan emphasizing whole-food nutrition, vitamin D repletion to 40–60 ng/mL, magnesium glycinate at night, and progressive resistance training raised total testosterone from 320 ng/dL to 760 ng/dL without medications. Thoracic mobility and hip hinge training improved recovery and adherence.
  • Post-DCIS symptom burden: In a patient more than a decade post-bilateral mastectomy with severe vasomotor symptoms, a carefully titrated transdermal estradiol patch with nightly progesterone, plus scapular mobility and postural rehabilitation, improved sleep and cognition. Shared decision-making and documented informed consent were essential.

Why Integrative Chiropractic Care Amplifies Endocrine Therapies

  • Autonomic regulation: Pain and joint dysfunction heighten sympathetic tone, disrupting sleep, glucose metabolism, and thyroid hormone conversion. Manual therapy, spinal mobilization, and breathing retraining shift HRV toward parasympathetic balance, creating a biological environment in which hormones function as intended.
  • Movement economy: Efficient biomechanics reduce inflammatory signaling from microtrauma and improve insulin sensitivity, crucial for PCOS, TRT safety, and thyroid action.
  • Adherence and feedback loops: Rapid musculoskeletal relief builds trust and momentum, making it easier to sustain nutrition, sleep, and medication regimens. Clinically, I consistently see greater lab improvements when patients are engaged in both structured movement and manual care.

Practical Protocol Checklists

Iron and ferritin

  • Assess ferritin, iron, TIBC, transferrin saturation, CRP, ESR, CBC, retic Hb.
  • Identify cause: menses, GI loss, malabsorption, diet, PPI use.
  • Replace with alternate-day dosing; recheck at 8–12 weeks.
  • Add diaphragmatic breathing and gentle conditioning.

Progesterone strategies

  • Start 100–200 mg oral micronized qHS; if intolerant, consider 50–100 mg sublingual divided.
  • For estrogen users, ensure endometrial protection.
  • In the history of endometriosis, there is a continued use of estrogen and progesterone even post-hysterectomy.

Cortisol evaluation

  • Use 4–5-point salivary cortisol to assess diurnal rhythm; AM serum for insufficiency screening.
  • Implement light therapy, sleep hygiene, and autonomic-balancing manual care.

Male fertility/TRT

  • For fertility: short-course clomiphene 3–6 months with lifestyle-based.
  • On TRT: monitor hematocrit, estradiol, SHBG, PSA, BP; address sleep apnea.
  • Optimize resistance training and recovery.

Thyroid optimization

  • If reverse T3 is high and symptoms persist, investigate inflammation and gut.
  • Consider T3 add-on or desiccated thyroid with careful monitoring.
  • Support with selenium, zinc, iron, and vitamin D; improve sleep and stress load.

Estriol/estradiol

  • Use local estradiol or estriol for urogenital symptoms; monitor if combining with estradiol systemically.
  • Expect estriol alone to be too weak for hot flashes.

Closing Perspective

Modern endocrine care thrives at the intersection of precise physiology and whole-person mechanics. When we calibrate hormones thoughtfully, correct nutrient deficits, and restore movement and autonomic balance, patients experience durable improvements in energy, cognition, metabolism, and quality of life. Integrative chiropractic care is not an add-on; it is a force multiplier—aligning the nervous system and musculoskeletal frame to receive and respond to biochemical therapies. My day-to-day observations mirror the literature: when we treat the individual and the system, outcomes follow.

References